A study on prevalence of antibiotic resistance was conducted in Russia

Print 04 June 2018
GMP News

GlaxoSmithKline (GSK) published the results of its Survey of Antibiotic Resistance (SOAR) in Russia. The collected data revealed high sensitivity of the main bacteria causing respiratory infections to amoxicillin/clavulanate and fluoroquinolones.

Data collected in the Russian Federation showed that the sensitivity of Streptococcus pneumoniae and Haemophilus influenzae to amoxicillin/clavulanate was 95% and 97.5%, respectively (100% under EUCAST and CLSI criteria). Russia also continues to demonstrate high sensitivity of both pathogens to fluoroquinolones (98.6% of Haemophilus influenzae isolates and up to 100% of S. Pneumoniae isolates are sensitive to anti-bacterial drugs of this class).

At the same time, the survey in Russia revealed a low level of sensitivity of S. Pneumoniae to macrolide antibiotics (clarithromycin, azithromycin) at the level of only 68.8%, while the sensitivity of Haemophilus influenzae to clarithromycin and azithromycin under EUCAST criteria did not exceed 0.4% and 2.2%, respectively.

Information obtained in the Russian Federation is consistent with the data on sensitivity of microorganisms observed in other countries and published earlier. SOAR enables practitioners to obtain contemporary data (2014-2016) on the state of antibiotic resistance in the treatment of community-acquired respiratory bacterial infections in Russia, as well as the information on worldwide trends in the formation of bacteria resistance to antibiotics.

Source

Return